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INTRODUCTION
A visit to a doctor for the treatment of a chronic medical condition generally
leads to a conversation about behavior changes and medications that will
ameliorate the condition. The same is not true for the treatment of alcoholism and
drug dependence-two of our nation's most costly medical conditions.1 Few
pharmacotherapies exist for the treatment of alcoholism and drug dependence,2 and
Copyright © 2010 by Ellen M. Weber.
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1. Alcoholism and drug dependence cost our nation an estimated $300 billion annually. Compare
Richard Saitz et al., The Case for Chronic Disease Management for Addiction, 2 J. ADDICTION MED. 55,
56 (2008), with NAT'L CTR. FOR CHRONIC DISEASE PREVENTION & HEALTH PROMOTION, CTRS. FOR
DISEASE CONTROL & PREVENTION, HEART DISEASE AND STROKE PREVENTION: ADDRESSING THE
NATION'S LEADING KILLERS 2 (2009), available at http://www.cdc.gov/chronicdisease/resources/
publications/AAG/pdf/dhdsp.pdf (estimating that the cost of heart diseases in 2009 totaled $304.6
billion).
2. Three medications are currently approved and prescribed for the treatment of alcoholism:
disulfiram (commonly known as Antabus), naltrexone (in both an oral and injectable formulation), and
acamprosate. CTR. FOR SUBSTANCE ABUSE TREATMENT, DEP'T OF HEALTH & HUMAN SERVS., HHS
PUB. NO. 09-4380, INCORPORATING ALCOHOL PHARMACOTHERAPIES INTO MEDICAL PRACTICE: A
TREATMENT IMPROVEMENT PROTOCOL (TIP) SERIES 49, at 4 (2009), available at
http://www.kap.samhsa.gov/products/manuals/tips/pdf/TIP49.pdf [hereinafter TIP 49]. Disulfiram is an
aversive agent that causes intense physical reactions if alcohol is consumed. Id. at 15. Naltrexone is an
opioid antagonist that curbs craving and reduces the rewarding effects of drinking, thereby promoting
abstinence and reducing the amount of heavy drinking. Id. at 28. Acamprosate is thought to normalize
alcohol-related changes in brain activity, thereby reducing symptoms of protracted withdrawal that may
trigger a relapse to drinking. Id. at 9.
Three medications-methadone, buprenorphine (in two formulations, Subutex and Suboxone)
and naltrexone-have been approved as safe and effective medications for the treatment of opioid
dependence. Gregory B. Collins & Mark S. McAllister, Buprenorphine Maintenance: A New Treatment
for Opioid Dependence, 74 CLEVELAND CLINIC J. MED. 514, 514-16 (2007) (describing use of
buprenorphine and methadone in treating opioid dependence); Patrick G. O'Connor & David A. Fiellin,
Pharmacologic Treatment of Heroin-Dependent Patients, 133 ANNALS INTERNAL MED. 40, 44-47
(2000) (describing use of naltrexone in treating opioid dependence). Methadone, a Schedule II
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remarkably few physicians prescribe those that do.3 Safe and effective medications,
used in conjunction with behavioral therapies, 4 can reduce alcohol and drug use and
the morbidity associated with addiction, and shorten the period between relapse and
resumed abstinence. 5 Yet most people who suffer from addiction visit a primary
controlled substance, is a long-acting, opioid agonist that prevents withdrawal and blocks the euphoric
effects of other illicit opioids. 21 U.S.C. § 812(c) (2006); David A. Fiellin & Patrick G. O'Connor, New
Federal Initiatives to Enhance the Medical Treatment of Opioid Dependence, 137 ANNALS INTERNAL
MED. 688, 688 (2002); O'Connor & Fiellin, supra, at 45-46. Buprenorphine, a Schedule III controlled
substance, is a partial opioid agonist that reduces craving, blocks the effect of other opioids, has a long
duration of action, and reduces adverse symptoms associated with opioid withdrawal. Hendr6e E. Jones,
Practical Considerations for the Clinical Use of Buprenorphine, SCI. & PRAC. PERSP., Aug. 2004, at 4,
4-5. Naltrexone, when used for opiate addiction, blocks the effect of self-administered opiates,
producing no stimulation, and seeks to break the habit of opiate addiction when ingested opiates fail to
produce the desired effect. NAT'L INST. ON DRUG ABUSE, NAT'L INSTS. OF HEALTH, NIH PUB. NO. 99-
4180, PRINCIPLES OF DRUG ADDICTION TREATMENT: A RESEARCH-BASED GUIDE 40 (2d. ed. 2009),
available at http://www.nida.nih.gov/PDF/PODAT/PODAT.pdf [hereinafter PRINCIPLES OF DRUG
ADDICTION TREATMENT]. No pharmacotherapy is available for cocaine dependence, although research
suggests that disulfiram may also be an effective medication for these patients. Markus Heilig & Mark
Egli, Pharmacological Treatment of Alcohol Dependence: Target Symptoms and Target Mechanisms,
111 PHARMACOLOGY & THERAPEUTICS 855, 859 (2006). Research has also focused on the development
of vaccines to treat cocaine dependence. See COMM. ON IMMUNOTHERAPIES & SUSTAINED-RELEASE
FORMULATIONS FOR TREATING DRUG ADDICTION, NAT'L RESEARCH COUNCIL, IMMUNOTHERAPIES
AND SUSTAINED-RELEASE FORMULATIONS FOR TREATING DRUG ADDICTION: BEHAVIORAL, ETHICAL,
LEGAL, AND SOCIAL QUESTIONS, app A-12, B-I5 (Henrick J. Harwood & S Tracy G. Meyers eds., pre-
publ'n copy 2004) (discussing testing for depot medications targeting cocaine).
3. See Suzanne E. Thomas & Peter M. Miller, Knowledge and Attitudes About Pharmacotherapy
for Alcoholism: A Survey of Counselors and Administrators in Community-Based Addiction Treatment
Centres, 42 ALCOHOL & ALCOHOLISM 113, 113 (2007) (discussing the reasons why pharmacotherapies
are not frequently used for alcoholism treatment).
4. Pharmacological and behavioral treatments are recommended to address both the
neuroadaptions in the brain that result from chronic drug and alcohol misuse as well as the behavioral
responses to stimuli and environment that trigger craving and can result in relapse. TIP 49, supra note 2,
at 5. Behavioral therapy may also help patients with alcohol dependence comply with pharmacotherapy
and promotes behavior change. Id. Pharmacotherapy and behavioral therapy are thought to operate
synergistically in the treatment of alcoholism. Id. The same is true for treatment of opiate dependence.
The National Institute on Drug Abuse has concluded that the most effective treatment for persons
participating in medication-assisted treatment for opioid dependence includes individual and group
counseling as well as provision of other medical, psychological, and social services. PRINCIPLES OF
DRUG ADDICTION TREATMENT, supra note 2, at 29. Federal regulations governing office-based use of
buprenorphine require physicians to demonstrate the capacity to refer patients for appropriate counseling
and other ancillary services in order to receive certification to prescribe this medication. 21 U.S.C.
§ 823(g)(2)(B)(ii) (2006 & West Supp. 2009).
5. Raye Z. Litten et al., Development of Medications for Alcohol Use Disorders: Recent Advances
and Ongoing Challenges, 10 EXPERT OPINION ON EMERGING DRUGS 323, 326-27 (2005); see also
Andrew J. Saxon & Dennis McCarty, Challenges in the Adoption of New Pharmacotherapeutics for
Addiction to Alcohol and Other Drugs, 108 PHARMACOLOGY & THERAPEUTICS, 119, 121 (2005) (setting
out research findings, including a seventy percent abstinence rate among patients in methadone
treatment programs compared to a six percent rate among untreated heroin-dependent persons; lower
rates of hospitalization for life-threatening conditions among patients in methadone programs; and
reduced hospitalization among HIV-infected individuals receiving drug abuse care); NAT'L INST. ON
DRUG ABUSE, NAT'L INSTS. OF HEALTH, NIH PUB. No. 99-4180, PRINCIPLES OF DRUG ADDICTION
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care physician and leave without an assessment for an alcohol or drug use problem
6
and, if appropriate, a prescription for therapeutic medications.7
The failure of physicians to prescribe pharmacotherapies for addiction goes to
the heart of our nation's failed drug policies. Although the reasons differ for the
limited prescribing practices for alcoholism and opioid dependence,8 they are
grounded in our nation's history of regulation of medical practice related to
narcotics addiction treatment; the paucity of medical training in addiction medicine;
persistent stigma associated with addiction disorders; and compensation barriers to
the effective treatment of this chronic medical condition.9 Succinctly stated, four
interrelated factors-context, competence, comfort, and compensation-affect
physician prescription practices in the United States.
A different picture emerges internationally. Physicians in the United
Kingdom, France, and Australia play an important role in the widespread
prescription of methadone and buprenorphine for the treatment of opioid
dependence, 0 and physicians across Europe widely prescribe acamprosate for
TREATMENT: A RESEARCH-BASED GUIDE 16 (1st ed. 1999) ("Methadone treatment has been shown to
decrease criminal behavior by as much as [fifty] percent.").
6. COMM. ON CROSSING THE QUALITY CHASM, INST. OF MED., IMPROVING THE QUALITY OF
HEALTH CARE FOR MENTAL AND SUBSTANCE-USE CONDITIONS 217 (2006) (noting that less than twenty
percent of general internal medicine physicians, obstetricians/gynecologists, family medicine physicians,
and psychiatrists "use[] any formal [alcohol] screening tool to detect problems among those [patients]
who did drink").
7. See Thomas & Miller, supra note 3, at 113 (noting that, while pharmacotherapies are
appropriate for alcohol use disorders, such treatments are not frequently used).
8. Naltrexone, for example, is not widely prescribed for the treatment of alcoholism, even by
addiction medicine specialists, because it is perceived to have limited efficacy. Heilig & Egli, supra note
2, at 860. The research literature suggests that patient response to naltrexone may vary based on genetic
features, and thus a lack of training in the indicated use of naltrexone (based on patient subtypes) may
account for the failure to prescribe this medication. Id.; see also Tami L. Mark et al., Understanding US
Addiction Physicians' Low Rate of Naltrexone Prescription, 71 DRUG & ALCOHOL DEPENDENCE 219,
221-23 (2003) (finding that physicians identified a patient's lack of compliance or willingness to take
naltrexone and medication cost as affecting prescribing practices as well as concerns about efficacy and
safety). Medications for the treatment of opiate dependence, on the other hand, are subject to special
federal regulation that precludes physicians from dispensing methadone in an office-based practice,
unless the physician is associated with an opioid treatment program, and requires additional training and
certification to prescribe buprenorphine. Jerome H. Jaffe & Charles O'Keeffe, From Morphine Clinics
to Buprenorphine: Regulating Opioid Agonist Treatment of Addiction in the United States, 70 DRUG &
ALCOHOL DEPENDENCE (SUPP. 1) S3, S7 (2003). Heightened regulatory standards also perpetuate the
stigma associated with opioid dependence and likely contribute to physician unwillingness and
discomfort in treating persons who are opiate dependent. See infra Parts 1.C-D.
9. See infra Parts I-Ill.
10. Maria Patrizia Carrieri et al., Buprenorphine Use: The International Experience, 43 CLINICAL
INFECTIOUS DISEASES (SuPP. 4) S197, S199-205 (2006) (describing France's general practitioner
prescription-based model, Australia's community-based pharmacy dispensing model, Italy's specialist
center model, Germany's primary physician and specialist clinic model, and Croatia's collaborative
treatment center and primary care physician model); Fiellin & O'Connor, supra note 2, at 691
(describing opioid agonist maintenance treatment in the U.K., Australia, and France); Michael Weinrich
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alcoholism. I I The World Health Organization, recognizing the importance of
treating opiate addiction and preventing HIV/AIDS among injection drug users,
added methadone and buprenorphine to its 14th Model List of Essential Medicines
in 2006.12 Although over-generalization may mask very real differences in the
physician practices in these other countries, many have adopted a harm reduction
model 13 to address addiction, which is viewed with suspicion in the context of the
United States' law enforcement and prohibitionist drug control model. 14 An
abstinence-based treatment philosophy continues to predominate our country's
treatment approach, 5 and is coupled with lingering ambivalence about whether
drug addiction is a disease that should be treated or a behavior that should be
punished. 16 The international experience, however, demonstrates the feasibility and
& Mary Stuart, Provision of Methadone Treatment in Primary Care Medical Practices: Review of the
Scottish Experience and Implications for US Policy, 283 JAMA 1343, 1343-44 (2000).
11. Litten et al., supra note 5, at 328; see also Mark et al., supra note 8, at 226 (noting that the
United States has the lowest rate of prescriptions for alcoholism medications-naltrexone, acamprosate
and disulfiram-per capita as compared to Australia, Canada, France, Germany, New Zealand, and the
United Kingdom).
12. Carrieri et al., supra note 10, at S 198; see also WORLD HEALTH ORG., WHO MODEL LIST OF
ESSENTIAL MEDICINES 21 (14th ed. 2005), available at http://whqlibdoc.who.int/hq/2005/
a87017-eng.pdf (listing methadone and buprenorphine and noting that each should be used within an
established support program).
13. See generally James L. Nolan, Jr., Harm Reduction and the American Difference: Drug
Treatment and Problem-Solving Courts in Comparative Perspective, 13 J. HEALTH CARE L. & POL'Y 31
(2010) (describing the harm reduction methods in England, Scotland, Ireland, Canada, and Australia).
Harm reduction is a public health model that "shifts the focus away from drug use itself to the
consequences or effects of addictive behavior" and offers policies and practices that are "designed to
reduce the harmful consequences of addictive behavior." G. Alan Marlatt, Basic Principles and
Strategies of Harm Reduction, in HARM REDUCTION: PRAGMATIC STRATEGIES FOR MANAGING HIGH-
RISK BEHAVIORS 49, 50 (G. Alan Marlatt ed., 1998). The use of pharmacoptherapies to reduce alcohol
and drug craving, prevent relapse, and treat opioid dependence falls within a harm reduction framework.
Id. at 61-62; see also Carrieri et al., supra note 10, at S199 (describing France's acceptance of harm
reduction in 1993 as a result of a notable increase in HIV infection among injection drug users).
14. Marlatt, supra note 13, at 49-50; Nolan, supra note 13, at 37, 41. For example, Congress has
only recently secured sufficient votes to end a twenty-one-year ban on the use of federal funds to
support needle exchange programs. Consolidated Appropriations Act, 2010, Pub. L. No. 111-117, 123
Stat. 3034 (2009). Data have consistently demonstrated that needle exchange programs reduce HIV
transmission without resulting in increased drug use, but Congress had not previously lifted the ban
amidst fear of increased injection drug use. Bill Piper & Naomi Long, Congress Gets Its Act Together:
Repeals Ban on Syringe Exchange Funding, Allows D.C. to Enact Medical Marijuana Program (Dec.
17, 2009), http://www.altemet.org/story/144638.
15. Marlatt, supra note 13, at 50; Nolan, supra note 13, at 36, 41; see also Saitz et al., supra note 1,
at 58 (noting that pharmacotherapies are underused in the addiction system); Saxon & McCarty, supra
note 5, at 123 ("Many of the [addiction treatment] staff members may have been trained in a self-help,
total abstinence-based orientation antithetical to the use of pharmacotherapy.").
16. See Richard J. Bonnie, The Virtues of Pragmatism in Drug Policy, 13 J. HEALTH CARE L. &
POL'Y 7, 10-17 (2010) (describing various drug policy perspectives).
[VOL. 13:49
2010] FAILURE OF PHYSICIANS TO PRESCRIBE PHARMACOTHERAPIES 53
value of expanding physician use of pharmacotherapy for alcoholism and drug
dependence.
17
The enactment of the Drug Addiction Treatment Act of 200018 (hereinafter
DATA 2000) created, for the first time in nearly a century, a real opportunity to
integrate pharmacotherapy addiction treatment into an office-based medical
practice in the United States. Under DATA 2000, physicians who receive training
and certification are permitted to prescribe buprenorphine-a Schedule 11' 9
Controlled Substance approved by the Food and Drug Administration (FDA) in
2002 for the treatment of opioid dependence.20 Since 2001, more than 24,000
physicians have been trained in the use of buprenorphine, and over 18,000 have
received certification.2' More than one million patients have been prescribed
17. The French experience with buprenorphine and methadone has reduced the overall harm
associated with untreated drug addiction, notwithstanding problems related to buprenorphine diversion.
Carrieri et al., supra note 10, at S201. From 1996, with the expansion of methadone and introduction of
buprenorphine, through 2003, the country found a five-fold reduction in the number of deaths
attributable to heroin; a six-fold reduction in the number of active injection drug users; and
approximately 3500 lives were saved. Id. at S199, S201. Croatia, which approved methadone treatment
under restrictive standards in 1996, reports an HIV infection prevalence rate among drug users of under
five percent. Id. at S204-05.
18. Children's Health Act of 2000, Pub. L. No. 106-310, § 3502, 114 Stat. 1101, 1222-27 (2000)
(codified at 21 U.S.C. § 823(g) (2006 & West Supp. 2009)).
19. Buprenorphine is a Schedule III medication because its pharmacological properties result in
little physical dependence and respiratory depression, and one of the FDA-approved formulations of the
medication, Suboxone, is designed to deter diversion and prevent misuse by the combination of
naloxone. Jones, supra note 2, at 5; see also Opioid Drugs in Maintenance and Detoxification Treatment
of Opiate Addiction; Buprenorphine and Buprenorphine Combination; Approved Opioid Treatment
Medications Use, 74 Fed. Reg. 29,153, 29,155-56 (proposed June 19, 2009) (providing evidence
demonstrating that the "scope and nature of abuse and diversion [of buprenorphine] are considerably
less than that of methadone and other Schedule II opioid drug products," and proposing modified
dispensing requirements of buprenorphine in opioid treatment programs).
20. The Controlled Substances Act requires practitioners who dispense narcotic drugs to
individuals for maintenance or detoxification treatment to obtain a special registration from the Drug
Enforcement Administration. 21 U.S.C. § 823(g)(1). DATA 2000 waives this requirement for qualifying
physicians who dispense and prescribe a Schedule 1II, IV, or V narcotic drug that has been approved by
the FDA for use in maintenance or detoxification treatment. Id. § 823(g)(2)(A)-(C). A qualifying
physician must have a state license and be certified in addiction medicine through subspecialty boards or
medical societies. Id. § 823(g)(2)(G)(ii). Alternatively, a licensed physician may become qualified by
participating in an eight-hour training session in the treatment and management of opioid-dependent
patients. Id. The physician must also have the capacity to refer patients for appropriate counseling and
other ancillary services. Id. § 823(g)(2)(B)(ii). As originally enacted, DATA 2000 limited the number of
patients each physician or group practice could serve to thirty patients. Fiellin & O'Connor, supra note
2, at 690. Congress eliminated the group practice limitation in 2005, Pub. L. No. 109-56, § 1, 119 Stat.
591, 591 (2005), and modified the patient limitation in 2006, permitting each physician to treat up to 100
patients, upon notification, after treating thirty patients for one year. Office of National Drug Control
Policy Reauthorization Act of 2006, Pub. L. No. 109-469, § 1102, 120 Stat. 3502, 3540 (2006) (codified
at 21 U.S.C. § 823(g)(2)(B)(iii)). DATA 2000, as amended, does not restrict the amount of medication a
physician is authorized to prescribe to a patient at any one time. 21 C.F.R. § 1301.28 (2009).
21. E-mail from Nicholas Reuter, Senior Pub. Health Analyst, Substance Abuse & Mental Health
Servs. Admin., to Ellen Weber, Professor of Law, Univ. of Md. Sch. of Law (Dec. 22, 2009) (on file
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buprenorphine since 2002, the majority of whom were new to substance abuse
treatment and dependent on non-heroin (prescription) opioids.22
The benefits of an office-based practice are substantial. Significantly more
patients can be treated for opioid dependence through the prescription of
buprenorphine in an office-based practice than in federally regulated opioid
treatment programs that prescribe and dispense methadone.23 The patients who seek
office-based care tend to be younger, have fewer years of opiate dependence, and
have lower rates of intravenous drug use and Hepatitis C than persons who receive
treatment in methadone programs. 24 Patients who seek care in an office-based
practice avoid both the stigma associated with obtaining care in a specialty
methadone clinic, and the strict daily attendance regimen imposed on patients
under federal regulations. 25 Finally, the co-location of addiction treatment in a
primary care practice facilitates the treatment of co-occuring health conditions,
such as HIV/AIDS, hepatitis, tuberculosis, and cardio-pulmonary disease, and over
with author) [hereinafter Reuter E-mail]. Physicians in all fifty states have received certification. E-mail
from Anthony Tommasello, Field Med. Advisor, Reckitt Benckiser Pharm., Inc., to Ellen Weber,
Professor of Law, Univ. of Md. Sch. of Law (Oct. 30, 2008) (on file with author).
22. Thomas F. Kresina et al., United States Government Oversight and Regulation of Medication
Assisted Treatment for the Treatment of Opioid Dependence, 2 J. DRUG POL'Y ANALYSIS 1, 10 (2009).
23. Cf Marc Auriacombe et al., French Field Experience with Buprenorphine, 13 AM. J. ON
ADDICTIONS (SuPP. 1) S 17, S 18-19 (2004) (demonstrating that treatment in European methadone clinics
only reached 20% to 30% of addicts because of regulations and safety concerns, but that allowing
office-based physicians to prescribe buprenorphine has increased patient treatment to 43%). In 2007,
approximately 265,000 individuals received medication-assisted treatment in opioid treatment programs
(OTPs), 99% of whom received methadone and 1% received buprenorphine. SUBSTANCE ABUSE &
MENTAL HEALTH SERVS. ADMIN., DEP'T OF HEALTH & HUMAN SERVS., NATIONAL SURVEY OF
SUBSTANCE ABUSE TREATMENT SERVICES (N-SSATS): 2007 DATA ON SUBSTANCE ABUSE TREATMENT
FACILITIES 41 (2008), available at http://wwwdasis.samhsa.gov/07nssats/nssats2k7web.pdf [hereinafter
N-SSATS]. The number of patients in OTPs has increased slightly from 227,000 in 2003 (21% of all
patients receiving treatment in specialized programs) to 265,000 in 2007 (23% of all patients). Id. at 26,
tbl.3.2. In comparison, in 2007, over 250,000 patients received a prescription for buprenorphine, and, in
2008, more than 425,000 patients did so. Reuter E-mail, supra note 21. Based on historical trends,
treatment capacity in OTPs will not increase significantly. The number of treatment facilities with OTPs
has remained fairly constant from 2003 to 2007; roughly 1200 facilities provide medication-assisted
treatment or 8% of all treatment facilities. N-SSATS at 19, tbl.2.3. The potential for increased physician
participation in prescribing buprenorphine exists, as only half of the 18,000 certified physicians
routinely prescribe medication. Reuter E-mail, supra note 21. Nothing impedes the certification of
additional physicians, although it is unclear whether significantly more physicians will receive
certification absent more comprehensive medical school and residency education regarding addiction
treatment. See infra Part II. The number of physicians obtaining the required DATA 2000 training
dropped sharply between 2008 and 2009, raising speculation as to whether the interest level among
currently licensed physicians has reached its capacity. Reuter E-mail, supra note 21.
24. Lynn E. Sullivan et al., The Practice of Office-Based Buprenorphine Treatment of Opioid
Dependence: Is It Associated with New Patients Entering Treatment?, 79 DRUG & ALCOHOL
DEPENDENCE 113, 114-16 (2005).
25. See Weinrich & Stuart, supra note 10, at 1346 (noting the avoidance of the stigma associated
with attending methadone clinics as one of the advantages of receiving treatment from a primary care
office); infra note 107 (discussing the strict pharmaceutical regime in specialty methadone clinics).
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time may destigmatize addiction treatment itself.26 The willingness of physicians to
prescribe pharmacotherapies means that more individuals will access treatment at
an earlier point in their disease and with fewer physical and mental complications.
27
Expansion of addiction treatment through mainstream medical treatment is
essential to provide care to the more than 18 million individuals who need
treatment for alcohol dependence, the 1.7 million individuals who need treatment
for dependence on pain relievers, and the nearly 300,000 individuals who need
treatment for heroin dependence.28
The substantial human, health care, and social benefits of expanding the
prescription of safe and effective pharmacotherapies for addiction treatment call for
strategies to eliminate barriers to physician prescribing. An understanding of those
barriers is the first step to expanding health care to millions of individuals who
could benefit from effective pharmacotherapies. Part I sets out the historical and
contemporary regulatory framework that has inhibited and, in some cases,
prevented physicians from prescribing pharmacotherapies for addiction treatment.29
Part II describes the failure of medical schools and residency programs to
adequately train physicians about addiction, which deprives them of the skills,
knowledge, and attitudes required to provide addiction treatment.3 ° Part III
identifies the compensation barriers that deter physicians from prescribing
medications for addictions. 31 The Article concludes with a very brief summary of
systemic changes that will be required to fully recognize the promise of new
medications .32
I. THE CONTEXT: REMOVAL AND REGULATION OF PHYSICIANS IN ADDICTION
TREATMENT
Federal regulation of physician prescription practices for narcotics treatment
over the past century has shaped current medical practice. This regulation has
essentially removed physicians from the delivery of addiction treatment, resulting
26. David A. Fiellin et al., Methadone Maintenance in Primary Care: A Randomized Controlled
Trial, 286 JAMA 1724, 1725 (2001).
27. See id. (noting that pharmacotherapies plays an important role in treating those with opioid
dependence and that office-based methadone maintenance would allow for greater access to treatment).
28. SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. DEP'T OF HEALTH & HUMAN
SERVS., HHS PUB. NO. 09-4434, RESULTS FROM THE 2008 NATIONAL SURVEY ON DRUG USE AND
HEALTH: NATIONAL FINDINGS 75 fig.7.2, 268 tbl.G.27 (2009), available at
http://oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.pdf [hereinafter NSDUH]. In 2008, 23 million people
needed treatment for an illicit drug or alcohol problem, but only 2.3 million received care in a
specialized facility. Id. at 83.
29. See infra Part I.
30. See infra Part 11.
31. See infra Part Ill.
32. See infra notes 176-85 and accompanying text.
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in the development of specialized facilities that provide such care.33 As the
following brief history of the federal regulatory framework demonstrates,
beginning around 1914 and running through most of the late-twentienth century,
federal law prohibited the prescription of controlled substances for the treatment of
narcotic addiction except by physicians working in highly regulated clinics.34 These
standards stigmatized medication-assisted treatment as well as the patients who
received such care, and left generations of physicians unprepared to diagnose and
treat patients with alcoholism and drug addiction.
A. Harrison Narcotics Act of 1914: Regulation of Physician Prescribing Practices
In the early twentieth century, the medical community viewed addiction as a
medical problem, and physicians prescribed opioid medications for the care of
addicted patients without legal restrictions. 35 Throughout the mid- to late-
nineteenth century, physicians regularly prescribed patent medicines that contained
morphine, cocaine and heroin.36 Medicines used as possible "cures" for morphine,
opium, and alcohol addiction also contained opiates, cocaine, and heroin,37 and
physicians prescribed such medications for the treatment and maintenance of
addiction.38 According to historian David Musto, the medical community was slow
to recognize that physicians were overusing morphine, that addiction to heroin,
morphine and cocaine was possible,39 and that these substances should be reduced
or removed from patent medicines.4 ° Public health officers involved in the
treatment of addiction at the turn of the century believed that physicians were
indeed responsible for the majority of individuals who developed drug addictions.4 1
33. Fiellin & O'Connor, supra note 2, at 690-91. Over 13,600 specialized treatment facilities
provide addiction treatment in the United States, and 8% of all facilities are OTPs that provide
methadone or buprenorphine. N-SSATS, supra note 23, at 18-19 tbls.2.2 & 2.3. Over 80% of facilities
provide outpatient treatment; 27% provide residential treatment in a non-hospital setting; and 7%
provide inpatient hospital care. Id. at 19 tbl.2.3. Over 57% of these specialty facilities are operated by
private non-profit organizations; 29% are private for-profit facilities; and approximately 12% are
operated by local, state, or federal government. Id. at 18 tbl.2.2. Over 60% of these facilities focus
primarily on substance abuse treatment services, and 29% have both substance abuse and mental health
services. Id.
34. See infra Part I.A-B.
35. DAVID F. MUSTO, THE AMERICAN DISEASE: ORIGINS OF NARCOTIC CONTROL 2-3 (3d ed.
1999).
36. Id.; see also United States v. Jin Fuey Moy, 241 U.S. 394, 402 (1916) ("[P]robably [a] very
large proportion of citizens... have some preparation of opium in their possession ... .
37. MUSTO, supra note 35, at 3, 5.
38. See id. at 77-79, 97-120 (discussing early attitudes of physicians that addiction was curable,
and various state and local methods of narcotics control).
39. Id. at 5. According to Musto, physicians themselves had one of the highest rates of addiction,
and "[tihe profession was commonly believed to be one of the causes of most of the other addicts in the
nation ... " Id. at 64.
40. Id. at 5.
41. Id. at 98-100.
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Responding to the development of a relatively large population of addicts and
"a fear of addiction and addicting drugs, ' '42 Congress enacted the Harrison
Narcotics Act of 1914.43 The Harrison Act was a revenue bill that required
physicians who prescribed preparations containing opium, cocaine, or their
derivatives, to register, pay an annual tax, write prescriptions for such medicines,
and maintain records of the patient and quantity of drugs dispensed. 4 The Act also
established restrictions on the quantity of opiates and cocaine that could be
contained in patent medicines.45 The Act did not directly prohibit physicians from
prescribing medicines containing opiates and cocaine, but it required prescriptions
to be issued "in the course of his professional practice only" and limited a patient's
possession of these drugs to those that had been prescribed in "good faith" by a
registered physician.46 The primary goal of federal narcotics control officials,
however, was to use the Harrison Act to stop physicians from both prescribing
opiates and cocaine to individuals with addictions and maintaining such individuals
on these drugs.47
Although federal enforcement efforts to halt the prescription of narcotics to
persons with addictions under the Harrison Act were rejected initially by the
Supreme Court,48 subsequent amendments to the Act strengthened the ability of the
42. Id. at 5.
43. Harrison Narcotics Act of 1914, Pub. L. No. 63-223, 38 Stat. 785, repealed by Comprehensive
Drug Abuse Prevention and Control Act of 1970, Pub. L. No. 91-513, 84 Stat. 1236 (codified as
amended at 21 U.S.C. §§ 801-971 (2006)).
44. See, e.g., United States v. Doremus, 249 U.S. 86, 90-93 (1919) (stating the Harrison Act's
statutory requirements); United States v. Jin Fuey Moy, 241 U.S. 394, 399-400 (1916) (reiterating the
statutory requirements).
45. MUSTO, supra note 35, at 60-61.
46. Linder v. United States, 268 U.S. 5, 13-14 (1925) (quoting the statute); Webb v. United States,
249 U.S. 96, 98-99 (1919) (noting the statutory requirements); Jin Fuey Moy, 241 U.S. at 400.
47. MUSTO, supra note 35, at 122-23.
48. See Jin Fuey Moy, 241 U.S. 394. The Supreme Court ruled that a physician could not be
indicted under Section 8 of the Harrison Act for conspiring to prescribe morphine to a patient who is
addicted to narcotics. Id. at 402. Federal officials asserted that Section 8 of the Harrison Act prohibited
any individual who was not registered and did not pay the special tax to possess the prohibited
substances, except to the extent the drug was prescribed "in good faith" by a registered physician. Id. at
399. The govemment further asserted that a drug prescribed to a patient addicted to opiates rather than
for medicinal purposes was not prescribed "in good faith." Id. The Court rejected the government's
broad assertion of police power that would "make the probably very large proportion of citizens who
have some preparation of opium in their possession criminal," and concluded that this provision only
applied to the class of individuals who were required to register under the Act. Id. at 402. The Court also
declined to interpret the parameters of "good faith" prescribing practices, ruling instead that the
provision was so vague that it might have been intended to apply to persons other than the patient. Id.;
see also MUSTO, supra note 35, at 126-27 (explaining that courts initially adopted the position that a
patient could not be found to have violated the Act, as they were not subject to registration, and
physicians were protected even if they prescribed for maintenance purposes as long as they had
registered).
JOURNAL OF HEALTH CARE LAW & POLICY
government to regulate physician practices and curtail addiction maintenance.49
Social and cultural change, fueled by the war effort and intense nationalism
following World War I, also increased public intolerance for alcohol and narcotic
use and cast addiction as immoral.50 According to Musto, by 1919, the country had
denounced the maintenance of both alcoholics, via the ratification of the Eighteenth
Amendment, and narcotic addicts, via robust enforcement of the Harrison Act.
51
A series of Supreme Court decisions, starting in 1919, barred physicians from
prescribing heroin and cocaine to patients with addictions, putting an end to
medication maintenance of addiction. In Webb v. United States,52 the Supreme
Court ruled that a physician's prescription for morphine that was given to "an
habitual user" to "keep him comfortable by maintaining his customary use" rather
than for purposes of attempting to "cure . . . the habit" was not a "prescription"
within the protection of the Harrison Act.53 In United States v. Doremus,54 issued
the same day as Webb, the Supreme Court upheld the indictment of a registered
physician who had sold a large quantity of heroin to a patient who was addicted to
narcotics without using the required prescription.5 The Court also upheld the
constitutionality of the Harrison Act as a tax measure that was intended to, among
other things, prevent a non-registered patient from reselling narcotics without
payment of the required tax.56 In United States v. Behrman,57 the Supreme Court
ruled that a physician's prescription of large quantities of heroin, cocaine, and
morphine to a patient who was known to be addicted did not fall into the
physician's regular course of professional practice. 58 Although the Court
recognized that physicians should be able to exercise their judgment in prescribing
different doses of medication in individual cases, it concluded that the "enormous
number of doses" prescribed to one patient "could only result in the gratification of
a diseased appetite for these pernicious drugs or result in an unlawful parting with
them to others in violation of the act ....
As a result of these decisions, a physician was not permitted to prescribe such
drugs, at least in large quantities, if drug addiction was the only disease being
49. MUSTO, supra note 35, at 130-31, 135-36. Among the amendments adopted in 1919 were the
imposition of a tax on narcotics and requirement for stamped packages. Id. The latter requirement was
intended to facilitate the prosecution of persons who possessed large quantities of drugs without a stamp.
Id.
50. Id. at 132-34.
51. Id.
52. 249 U.S. 96 (1919).
53. Id. at 99-100.
54. 249 U.S. 86 (1919).
55. Id. at 92, 95.
56. Id. at 93-95.
57. 258 U.S. 280 (1922).
58. Id. at 287-89.
59. Id. at 288-89.
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treated.60 The heightened threat of prosecution deterred most physicians from
providing care to patients with addictions, even if they prescribed within the legal
limits.
6
B. Narcotics Clinics: Early Model of Medication-Assisted Treatment
of Opioid Addiction
The model for contemporary specialized medication-assisted treatment
programs also originated during the first quarter of the twentieth century.62 Initially
sympathetic to the health concerns of persons who had developed addictions,
federal and state health officials and local law enforcement,63 beginning around
1912, created maintenance clinics in a dozen states that would prescribe medication
in an effort to prevent suffering related to addiction and wean individuals from their
drug use through the gradual reduction of dosage. In Jacksonville, Florida, for
example, the City health officer established a clinic in which persons with
addictions could receive free narcotics prescriptions.64 In Tennessee, persons with
addictions were registered and given refillable opiate prescriptions to minimize
suffering and reduce illegal drug trafficking.65 In New York, a series of laws and
policy directives enforced between 1913 and 1920 permitted maintenance of
persons with addictions by private physicians; these measures also provided for
increased regulation of physician practices, patient registration requirements, and
the establishment of state-run narcotics clinics for both the maintenance and
treatment of addiction.66 With a narcotics clinic system in place, state narcotic
60. But see Linder v. United States, 268 U.S. 5 (1925). The Supreme Court in Linder recognized
the right of physicians to prescribe "moderate amounts of drugs for self-administration in order to
relieve conditions incident to addiction" without violating the Harrison Act. Id. at 22. The Court,
emphasizing the limitations of the Harrison Act as a revenue measure, acknowledged that the federal
government had no authority to exercise "direct control of medical practice in the [s]tates .... Id. at 18.
The Court, reversing the physician's conviction, concluded that he did not "transcend[] the limits of...
professional conduct" by prescribing a small dose of morphine and cocaine to a patient with narcotic
addiction to relieve pain resulting from stomach cancer or an ulcer. Id. at 16, 22-23. The Court also
painted a more sympathetic view of patients with addictions as "diseased and proper subjects for such
treatment," id. at 18, at least to the extent they were not involved in the diversion of narcotics, id. at 22.
61. MUSTO, supra note 35, at 184-85. In 1970, in enacting legislation to repeal the Harrison Act,
Congress noted that "[tihere are relatively few practicing physicians in the U.S. today who treat narcotic
addicts because of the uncertainty as to the extent to which they may prescribe narcotic drugs for addict
patients." INST. OF MED., FEDERAL REGULATION OF METHADONE TREATMENT 123 (Richard A. Rettig &
Adam Yarmolinsky eds., 1995) [hereinafter FEDERAL REGULATION OF METHADONE TREATMENT].
62. See MUSTO, supra note 35, at 97-98 (describing the innovation of the city drug clinic in
Jacksonville, Florida in 1912).
63. Id. at 97-98, 151. Law enforcement recognized that maintenance clinics were effective in
reducing crime. Id. at 168 (indicating that the clinic in Shreveport, Louisiana was supported by the
federal District Court Judge, chief of police, and sheriff); id. at 177 (noting that clinics in New Haven,
Connecticut were under the supervision of police surgeons who were paid for by the police department).
64. Id. at 97.
65. Id. at 100.
66. Id. at 102-20.
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control officials intended to revoke the prescribing authority of physicians who
refused to adhere to prescription limitations or dosages deemed to be consistent
with "curing" addiction. 67  Federal and State officials also promoted
institutionalized care to help patients withdraw from drugs, 68 even though that care
proved relatively ineffective as patients could resume use by attending a narcotics
clinic.
69
By 1920, federal officials had resolved to close maintenance clinics. The
operation of clinics by local health departments was a continuing source of "legal"
drug maintenance, which, by this time, was unlawful under Webb and Doremus.
70
Maintenance clinics also made enforcement of the Harrison Act against private
physicians who abused prescription standards difficult, since both provided
essentially the same care.7' Discouraged by the failure of maintenance clinics and
hospitals to cure addiction, some public health officials had come to believe that
elimination of drug availability was the best hope of a successful cure.72 Although
not supported by evidence from the treatment provided in hospitals, some of the
most ardent supporters of a medical model began to endorse abrupt withdrawal
from narcotics.73 The American Medical Association issued a resolution in 1920
opposing ambulatory maintenance clinics and condemning the use of heroin,74
which sanctioned the further prosecution of physicians who continued to prescribe
maintenance medication.75
Federal and state initiatives to address addiction as a disease ended by the
mid-1920s. All maintenance clinics were shuttered by 1925,76 and the federal
government adopted a supply-side strategy to eliminate drug addiction through
strict law enforcement and international treaties.77 Opiate and cocaine dependence
67. Id. at 116.
68. Id. at 141-42. Treasury Department officials envisioned a nationwide system of hospitals that
would provide treatment to persons who would suffer from the abrupt denial of drugs through the
increasingly strict enforcement of the Harrison Act. Id. at 141-43. Federal legislation was introduced in
1919 that would have provided federal matching funds to states that would establish and maintain
hospitals. Id. at 143-44. The legislation, dependent on a hefty appropriation at a time of economic
recession, failed to pass. Id. at 144, 155.
69. Id. at 119.
70. Id. at 119-20 (concluding that Webb and Doremus "essentially outlawed the maintenance of
addiction and even the reduction method and ambulatory treatment").
71. Id. at 149.
72. Id. at 144-46, 149, 162.
73. Id.
74. Id. at 148; Jaffe & O'Keeffe, supra note 8, at S3 (noting that by 1920 the AMA condemned
prescribing opioids to addicts).
75. Jaffe & O'Keeffe, supra note 8, at S3.
76. MUSTO, supra note 35, at 173, 177.
77. Id. at 181-82.
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were no longer considered a medical problem but rather a criminal justice issue. 78
This history "became part of the 'lore' that affected medical practice and research
for almost 50 years and had a profound influence on government officials when the
issue of narcotic maintenance again emerged in relation to methadone.,
79
C. Regulation of Methadone Maintenance Treatment: Resurrection of a
Clinic-Based Model of Care to Prevent Drug Diversion
1. Physicians Barred from Prescribing Methadone for Treatment ofAddiction
in Office-Based Practice
The current regulatory scheme for medications that are approved to treat
opiate addiction 80 continues to restrict physician practice and impose federal
oversight that is unprecedented for the prescription of FDA-approved medications,
including Schedule II drugs. 81 The regulatory framework dates back to the 1960s
when research conducted by Drs. Vincent Dole and Marie Nyswander determined
that methadone, a synthetic opiate that had been used in the late 1950s for
78. Federal prisons became so overcrowded with drug-addicted prisoners by the 1920s that
Congress enacted legislation that led to the establishment, in the mid-1930s, of two prisons in
Lexington, Kentucky, and Fort Worth, Texas for the incarceration of narcotic addicts. Id. at 204-06.
These prisons were run by the Public Health Services, with oversight by both the Justice Department
and Federal Bureau of Narcotics, and were eventually turned into hospitals at which addiction treatment
research was conducted. Id. at 205-06. Foreshadowing the importance of medications to treat opiate
dependence, some of the initial studies concluded that less than ten percent of persons with chronic
addictions were able to maintain abstinence after discharge from long-term treatment that offered only
psychiatric care and counseling. FEDERAL REGULATION OF METHADONE TREATMENT, supra note 61, at
38.
79. FEDERAL REGULATION OF METHADONE TREATMENT, supra note 61, at 121.
80. The Harrison Act was repealed in 1970 with the enactment of the Comprehensive Drug Abuse
Prevention and Control Act of 1970, Pub. L. No. 91-513, 84 Stat. 1236. The 1970 Act addressed the
"research, treatment, and prevention of drug abuse and dependence" as well as "drug abuse law
enforcement authority." See FEDERAL REGULATION OF METHADONE TREATMENT, supra note 61, at 123.
One purpose of the Act was "to clarify for the medical profession ... the extent to which they may
safely go in treating narcotic addicts as patients." Id. Title 11 of the Act was the Controlled Substances
Act, which classified all substances under five schedules based on their abuse potential, psychological
and physical effects, and medical uses. Tit. 11, 84 Stat. at 1242-84 (codified at 21 U.S.C. §§ 801-971).
81. See Jaffe & O'Keeffe, supra note 8, at S5 (noting that clinicians have criticized federal
regulations as "a burdensome interference with the practice of medicine"). Three layers of federal
regulatory oversight by the FDA, Drug Enforcement Administration (DEA), and Department of Health
and Human Services (formerly the Department of Health, Education and Welfare) governed the use of
methadone for detoxification and maintenance treatment of opiate addiction for over 30 years. FEDERAL
REGULATION OF METHADONE TREATMENT, supra note 61, at 135. As of 2001, the FDA transferred its
oversight responsibility to the Substance Abuse and Mental Health Administration within the
Department of Health and Human Services. Opioid Drugs in Maintenance and Detoxification Treatment
of Opiate Addiction, 66 Fed. Reg. 4076, 4076 (Jan. 17, 2001) (codified at 42 C.F.R. pt 8). DEA's
oversight and registration requirements for physicians who seek to use methadone for the treatment of
addiction remain in place. See infra note 95 (detailing registration and competency requirements for
physicians who desire to dispense narcotic drugs in connection with addiction treatment).
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detoxification treatment for heroin dependence, 82 could be used as a maintenance
medication to effectively treat heroin dependence.83 Treatment centers, operating
under Investigational New Drug applications issued by the FDA, began prescribing
methadone for addiction treatment under the disguise of research 84 and claimed
exemption from the Federal Bureau of Narcotics' policies that still rendered the
dispensing of opioids to addicts illegal.85 In 1972, in response to the dramatic
expansion of methadone treatment and concerns about the abuse and diversion of
this medication, the FDA, in collaboration with the Special Action Office for Drug
Abuse Prevention and the Bureau of Narcotics and Dangerous Drugs (the
predecessor to the DEA), promulgated regulations86 that authorized the use of
methadone maintenance treatment under strict and close control to ensure safe
distribution, administration, and dispensing.87
The regulatory framework itself was antithetical to the integration of
addiction treatment into mainstream medical practice: it restricted the availability
of methadone to approved programs and hospital pharmacies,88 and precluded
private physicians from prescribing medication for addiction treatment unless they
were approved as a "program" and met all requirements of the regulation including
82. FEDERAL REGULATION OF METHADONE TREATMENT, supra note 61, at 39. Methadone was also
used in the late 1940s by the Lexington, Kentucky narcotic hospital as a treatment for opiate withdrawal
syndrome, id. at 125-26, and had been approved by the FDA in 1947 for the treatment of pain, id. at 10.
83. Id. at 126.
84. Id. at 128.
85. Jaffe & O'Keeffe, supra note 8, at S4.
86. Approved New Drugs Requiring Continuation of Long-Term Studies, Records, and Reports;
Listing of Methadone with Special Requirements for Use, 37 Fed. Reg. 26,790, 26,790 (Dec. 15, 1972)
(codified at 21 C.F.R. pt. 130) (repealed by Opioid Drugs in Maintenance and Detoxification Treatment
of Opiate Addiction, 66 Fed. Reg. at 4076).
87. FEDERAL REGULATION OF METHADONE TREATMENT, supra note 61, at 123, 132.
88. 21 C.F.R. § 130.44(b)(1)(i), (iii) (1973); FEDERAL REGULATION OF METHADONE TREATMENT,
supra note 61, at 130. According to Dr. Jerome Jaffe, the Director of the Special Action Office for Drug
Abuse Prevention in 1972, the drafters of these regulations did not "intend for medication dispensing to
be forever limited to a few large clinics. Although they recognized that access to treatment by individual
physicians might temporarily be limited, they believed that the regulations would be revised as
knowledge expanded and as opioid maintenance treatment became less controversial." Jaffe &
O'Keeffe, supra note 8, at S5. The future model would be one in which individual practitioners would
be linked to pharmacies and other sites that would be authorized to dispense drugs for the treatment of
addiction. Id. This model has never been realized in the United States, albeit implemented effectively in
research settings. Fiellin et al., supra note 26, at 1725-26, 1729. It is also a well-established model of
care in the United Kingdom and other countries. See Phillip 0. Coffin et al., Support for Buprenorphine
and Methadone Prescription to Heroin-Dependent Patients Among New York City Physicians, 32 AM. J.
DRUG & ALCOHOL ABUSE 1, 5 (2006) (describing pharmacy practices to dispense methadone in
Scotland and Australia); Jennifer McNeely et al., Office-Based Methadone Prescribing: Acceptance by
Inner-City Practitioners in New York, 77 J. URB. HEALTH 96, 101 (2000) (describing the "shared care"
system of care in the United Kingdom in which addiction specialists support a network of primary care
physicians caring for methadone patients).
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staffing requirements.89 The regulations also dictated who would be eligible for
methadone treatment (based on an individual's age and duration of drug
dependence), maximum initial doses, minimum amount of counseling, urinalysis
testing, and the factors used to determine a patient's eligibility for non-supervised
administration of ("take-home") medication.90 These standards not only usurped
individualized medical determinations for patient care but also institutionalized a
stigma surrounding patients in methadone treatment. Patients were required to
obtain care in separate, free-standing programs and to take their medication on a
daily basis under directly observed administration for substantial periods of time.91
States were also authorized to impose additional restrictions on patients who
92participated in methadone treatment.
Two years later, Congress enacted the Narcotic Addict Treatment Act of
1974, 93 which was intended to complement the FDA regulations and clamp down
further on what Congress considered to be inappropriate prescribing practices by
physicians.94 This Act amended the Controlled Substances Act to require annual
registration of practitioners and treatment sites with the Drug Enforcement
Administration (DEA)95 and authorized the DEA to regulate the storage and
security of drugs used to treat addiction.
96
89. § 130.44(b)(l)(iv), (d)(4) (requiring one physician, two nurses, and four counselors for every
300 patients). Under the regulations, a methadone treatment "program" was required to provide
comprehensive services including counseling, rehabilitation, and other social services, such as
vocational and educational guidance and employment placement in addition to dispensing methadone.
Id. § 130.44(b)(1)(ii); see FEDERAL REGULATION OF METHADONE TREATMENT, supra note 61, at 130. A
program was required to obtain approval from the FDA and a state-based authority, § 130.44(c)(4), and
approval was contingent on DEA approval of the physical site at which the medication would be
dispensed and certification of compliance with the Controlled Substances Act. Id. § 130.44(c)(5);
FEDERAL REGULATION OF METHADONE TREATMENT, supra note 61, at 130. These standards effectively
precluded physicians not affiliated with a treatment program from prescribing the medication.
90. § 130.44(d); Jaffe & O'Keeffe, supra note 8, at S4.
91. § 130.44(d)(7)(i). Patients were required to take medication under direct observation for at least
six days a week for a three-month period; those who demonstrated substantial progress in rehabilitation
and could demonstrate that daily attendance interfered with employment, education, or home-making
responsibilities were eligible for a two-day, take-home supply of medication. Id. A three-day, take-home
supply was not offered until the patient had participated successfully in treatment for two years. Id. No
patient was afforded a week's supply of take-home medication until he or she had participated
successfully in treatment for three years. Fiellin et al., supra note 26, at 1726.
92. Jaffe & O'Keeffe, supra note 8, at S5. Four states-Montana, Wyoming, South Dakota, and
North Dakota-have no certified opioid treatment programs. U.S. GOV'T ACCOUNTABILITY OFFICE,
Pub. No. GAO-09-341, METHADONE-ASSOCIATED OVERDOSE DEATHS: FACTORS CONTRIBUTING TO
INCREASED DEATHS AND EFFORTS TO PREVENT THEM 6 n.13 (2009) [hereinafter METHADONE-
ASSOCIATED OVERDOSE DEATHS]. Five other states-Idaho, Mississippi, New Hampshire, Vermont,
and West Virginia-have instituted programs since 2001. Saxon & McCarty, supra note 5, at 122.
93. Pub. L. No. 93-281, 88 Stat. 124 (1974) (codified as amended at 21 U.S.C. § 823(g)(1) (2006 &
West Supp. 2009)).
94. FEDERAL REGULATION OF METHADONE TREATMENT, supra note 61, at 134-35.
95. Id. Under the Controlled Substance Act, a physician who seeks to dispense narcotic drugs for
maintenance treatment or detoxification must obtain a separate DEA registration for such purpose.
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2. Regulatory Revision But Rejection of Opportunities for Physician Office-
Based Practice
This federal regulatory framework for methadone maintenance treatment
remained in place for thirty years, notwithstanding recommendations to
dramatically revamp the standards so that patients would have greater access to this
effective medication for opiate addiction. In 1995, the Institute of Medicine (IOM)
concluded that "no compelling medical reason [exists] for regulating the
therapeutic use of methadone differently from any other Schedule II controlled
substance. 97 It found that the regulations had deprived society of reaping the full
benefit of methadone as an effective treatment for addiction and preventative
measure for other public health problems and crime.98 According to the 1OM, the
extraordinary regulatory controls had prevented some individuals from obtaining
treatment tailored to their needs; prevented doctors from exercising professional
judgment in treating patients; and resulted in the isolation of treatment programs
from mainstream medical practice.99 The IOM recommended, among other things,
that the regulations be reduced in scope, supplemented by clinical practice
guidelines that shift responsibility for treatment decisions from regulators to
clinicians,100 and provide for maintenance treatment outside of a licensed treatment
program. 10 1
Long-overdue revisions to the federal methadone regulations, promulgated in
2001, have moved in the direction of a clinical practice model by instituting an
accreditation and certification scheme for programs, 0 2 but do little to encourage or
enable physicians to establish an office-based model for dispensing methadone.
The Department of Health and Human Services (HHS) rejected recommendations
to develop standards that would permit physicians to prescribe methadone in office-
§ 823(g)(1). Registration is contingent upon an HHS finding that the physician is qualified under its
regulatory standards; the DEA determining that the physician will comply with security standards for
storing narcotic drugs and record-keeping requirements; and HHS finding that the physician will comply
with standards related to the amount of narcotic permitted to be given to a patient for unsupervised use
(i.e. take-home medication). Id.
96. Jaffe & O'Keeffe, supra note 8, at S5.
97. FEDERAL REGULATION OF METHADONE TREATMENT, supra note 61, at 219.
98. Id. at 30-31.
99. Id. at 31.
100. Id. at 221, 204. The IOM was particularly critical of the arbitrary restrictions on physician and
clinical practice in the context of dictating the length of treatment and limiting take-home medication for
the sole purpose of controlling diversion. Id. at 220.
101. Id. at 204.
102. Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction, 66 Fed. Reg.
4076, 4076 (Jan. 17, 2001) (codified at 42 C.F.R. pt. 8). OTPs are required to obtain accreditation from a
national body that evaluates the program's compliance with federal opioid treatment standards, 42
C.F.R. § 8.4(a) (2009), and certification from the Substance Abuse and Mental Health Services
Administration. Id. § 8.11(a)(2). Certification is based on the OTP obtaining accreditation and
demonstrating compliance with programmatic standards and any other conditions. Id.
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based settings without affiliation with an opioid treatment program (OTP), citing
"the lack of trained and experienced practitioners to diagnose, admit, and treat
opiate addicts who are not sufficiently stabilized without the support of an OTP.
103
Although a physician could theoretically seek accreditation and certification for an
office-based practice, the cost associated with satisfying these requirements make it
impractical for a physician who is not associated with an existing program to do
so.' ° 4 The regulations instead seek to gradually increase treatment capacity in
office-based practices by authorizing "medical maintenance" of stabilized patients
who, after two years of continuous treatment, may be permitted to have a one-
month supply of medication 10 5 and may be referred to physicians who maintain
formal arrangements with OTPs.'0 6 Apart from this limited expansion, the current
regulations reduce, albeit not substantially, the restrictions on patient attendance
requirements and take-home (unsupervised) medication privileges.'0 7 The federal
regulations continue to weight the risk of diversion'0 8 as more salient than clinical
judgment, individualized patient care, and strategies to encourage patients to enter
treatment earlier in the course of their addiction.' 09
Nearly a decade later, modification of federal regulatory standards to reduce
barriers to office-based methadone practice seems unlikely. A sharp increase in
methadone-related overdose deaths, dating from 2002, linked to the increased
availability of methadone for pain management from private physicians," 0 has
103. 66 Fed. Reg. at 4079. The Department also cited the current DEA regulations, which do not
permit registrants to prescribe narcotics for addiction treatment, as a regulatory standard that barred this
model. Id.
104. Jaffe & O'Keeffe, supra note 8, at S7; see also 66 Fed. Reg. at 4079 (noting comments that
accreditation and certification would be "prohibitively expensive for individual physicians").
105. § 8.12(i)(3)(vi).
106. 66 Fed. Reg. at 4079; § 8.1 1(h) (setting out a process whereby the OTP may seek an exemption
from any programmatic standard, including permitting a private physician to treat a limited number of
patients without satisfying certain staffing and service standards).
107. Patients are allowed a single take-home dose for a day the clinic is closed and must demonstrate
compliance with treatment, stability in home environment, and an absence of criminal activity and drug
and alcohol use to be eligible for additional take-home medication. § 8.12(i)(l)-(2). Patients deemed
eligible for unsupervised administration of medication are restricted to one additional take-home dose
during the first ninety days of treatment; two additional doses per week for the next three months; three
additional doses per week for up to nine months; and a maximum six-day supply for the remainder of
the first year in treatment. Id. § 8.12(i)(3). Patients must participate in treatment continuously for one
year before receiving a two-week, take-home supply of medication. Id. The IOM recommended a far
more generous take-home schedule after the first three months of treatment, with medical maintenance
beginning after one year in treatment. FEDERAL REGULATION OF METHADONE TREATMENT, supra note
61, at 199-200.
108. § 8.12(i) (stating that "take-home" standards are designed "[t]o limit the potential for diversion
of opioid agonist treatment medications to the illicit market").
109. See FEDERAL REGULATION OF METHADONE TREATMENT, supra note 61, at 200 (outlining the
therapeutic value of a more flexible take-home medication policy).
110. METHADONE-ASSOCIATED OVERDOSE DEATHS, supra note 92, at 18-24 (finding that a "[l]ack
of knowledge about [methadone's] unique pharmacological properties among practitioners" who
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resulted in a call by some in Congress for increased regulation of prescription
practices for methadone."' Addiction treatment experts, undoubtedly wary of a
backlash to advances in office-based care for individuals with histories of opiate
dependence, 12 have urged caution in imposing new regulations, which would deter
the use of beneficial medications." 3 They instead recommend that private
physicians follow patient-centered practices that include understanding a patient's
history of alcohol and drug use, adjusting care management for patients with
substance use histories, and implementing practices to ensure that patients store
medications securely, use prescribed medications appropriately, and are monitored
for diversion."14
D. Federal Regulation of Buprenorphine: Opportunity to Provide Addiction
Treatment in Office-Based Settings
The enactment of DATA 2000 and the FDA's approval of buprenorphine for
office-based practices in 2002 have increased access to opioid addiction treatment
in a range of health care settings." 5 Keenly aware of the history regarding addiction
maintenance in the 1920s, the limited scope of medical education related to
addiction treatment, and the regulatory strictures and stigma associated with
methadone maintenance treatment, the federal government and the manufacturer of
buprenorphine have taken important steps to ensure appropriate prescription
practices while expanding access to office-based care. They have developed
prescribe methadone for pain "and [their) patients as well as abuse of diverted methadone . . . have
contributed to" the rise of methadone-associated deaths; and reporting that the increase in deaths tracked
to the increase in methadone used for pain managements rather than its use in OTPs); see also Aron J.
Hall et al., Patterns of Abuse Among Unintentional Pharmaceutical Overdose Fatalities, 300 JAMA
2613, 2616-17 (2008) (in study of overdose pharmaceutical deaths in West Virginia, 56% of decedents
had not been prescribed the drugs; 63% of deaths associated with pharmaceutical diversion; and 21%
with "doctor-shopping").
I 1l. See Methadone Treatment and Protection Act of 2009, S. 754, 111 th Cong. (2009) (calling for
increased federal oversight of methadone as used in treatment of pain and addiction, including
amendment of the Controlled Substances Act to require a sixteen-hour training program for practitioners
to be registered to prescribe methadone or other opioids; establishment of dosing standards for pain
management and addiction treatment and benchmark standards for reduction of methadone abuse; and
elimination of unsupervised take-home medication for patients when OTP is closed for business).
112. METHADONE-ASSOCIATED OVERDOSE DEATHS, supra note 92, at 25. S. 754 would impose
additional restrictions on methadone treatment programs, even though the GAO, in its report requested
by the sponsor of the bill, found virtually no relationship between the increase of methadone-associated
deaths and OTP prescription and security practices. Id. at 19-20, 22-23.
113. A. Thomas McLellan & Barbara Turner, Prescription Opioids, Overdose Deaths, and
Physician Responsibility, 300 JAMA 2672, 2672 (2008) (responding to Hall and colleagues, supra note
110, prior to McLellan becoming the current Deputy Director for Demand Reduction, Office of National
Drug Control Policy).
114. ld. at 2673.
115. See supra notes 18-28 and accompanying text,
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clinical practice guidelines," I6 risk management strategies,1l7 and physician
education and on-going clinical support 118 with a cadre of physician-leaders. 119
Anticipating reluctance among physicians to prescribe buprenorphine for addiction
treatment out of fear of disciplinary actions, the federal government has encouraged
the Federation of State Medical Boards to develop a model policy guideline that
recommends physicians assess all patients for substance abuse and sets out
guidelines for prescribing buprenorphine consistent with legitimate medical
purposes. 120 The federal government publicizes the growing number of certified
physicians and maintains a web-based physician locater to aid individuals who are
seeking care. 121 It has also funded a range of demonstration projects to evaluate
best practices in providing office-based care. 122 Finally, whenever evidence of
diversion of buprenorphine has emerged, federal and state officials have responded
quickly 123 to prevent the most drastic of regulatory solutions-rescheduling
116. E.g., CTR. FOR SUBSTANCE ABUSE TREATMENT, U.S. DEP'T OF HEALTH & HUMAN SERVS.,
DHHS PUB. NO. 04-3939, CLINICAL GUIDELINES FOR THE USE OF BUPRENORPHINE IN THE TREATMENT
OF OPIOID ADDICTION: A TREATMENT IMPROVEMENT PROTOCOL (TIP) SERIES 40 (2004), available at
http://buprenorphine.samhsa.gov/Bup-Guidelines.pdf [hereinafter TIP 40].
117. See, e.g., Letter from H. Westley Clark, Dir., Ctr. for Substance Abuse Treatment (Apr. 3,
2006), available at http://buprenorphine.samhsa.gov/CompoundingandSellingBuprenorphine.pdf
(indicating that Reckett-Benckiser Pharmaceuticals, Inc. administers a comprehensive Risk Management
Program designed to reduce the risks and consequences of the diversion of buprenorphine).
118. See, e.g., Letter from H. Westley Clark, Dir., Ctr. for Substance Abuse Treatment (Jan. 13,
2006), available at http://buprenorphine.samhsa.gov/LocatorDisclosureRequest.pdf (describing a
Physician Clinical Support System, established under the Center for Substance Abuse Treatment, to
provide a national mentoring network for physicians treating opioid dependence).
119. See infra Part 11 for a discussion of the importance of leaders within the medical profession to
encourage adoption of new medical practices and pharmacotherapies.
120. FED'N. OF STATE MED. BDS. OF THE U.S., INC., MODEL POLICY GUIDELINES FOR OPIOID
ADDICTION TREATMENT IN THE MEDICAL OFFICE (April 2002), available at http://www.fsmb.org/pdf/
2002_grpolOpioidAddictionTreatment.pdf ("Qualified physicians need not fear disciplinary action
from the Board or other state regulatory or enforcement agency for appropriate prescribing, dispensing
or administering approved opioid drugs in Schedules Ill, IV, or V, or combinations thereof, for a
legitimate medical purpose in the usual course of opioid addiction treatment.").
121. Substance Abuse & Mental Health Servs. Admin., U.S. Dep't of Health & Human Servs.,
Buprenorphine Physician and Treatment Program Locator, http://buprenorphine.samhsa.gov/
bwnslocator/index.html (last visited Feb. 19, 2010).
122. See, e.g., Kresina et al., supra note 22, at 16 (identifying the conclusion of a five-year project
by the Health Services and Resources Administration to study the integration of buprenorphine
treatment into HIV primary care).
123. For example, in 2006, the Substance Abuse and Mental Services Administration responded to
reports of diversion and abuse of buprenorphine by commissioning an independent assessment of the
problem. See JBS INT'L, INC., DIVERSION AND ABUSE OF BUPRENORPHINE: A BRIEF ASSESSMENT OF
EMERGING INDICATORS (Nov. 30, 2006), available at http://buprenorphine.samhsa.gov/
BuprenorphineFinalReport 12.6.06.pdf. The report concluded that diversion and abuse were
concentrated in certain geographic regions and primarily involved attempts to self-medicate with
buprenoprhine when formal treatment was not available as well as some illegal importation from outside
the United States. Id. at 1. Maryland's health department responded to a highly critical newspaper series
on buprenorphine, which highlighted medication diversion, see, e.g., Fred Schulte & Doug Donovan,
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buprenorphine as a Schedule II controlled substance-that would reverse the gains
that have been achieved through office-based practice.1
24
Regulatory 125 and non-regulatory obstacles-some of which are the collateral
consequences of the past century's restrictions on medical practice-continue to
limit access to buprenorphine in an office-based practice. In late 2009, speculation
surfaced about the DEA's desire to suppress the number of physicians who
prescribe buprenorphine when the enforcement agency informed DATA 2000
waiver practitioners of its plans to inspect their practices. 126 For many, the DEA's
action reflected its "reputation among some doctors for choosing heavy-handed
enforcement over patient needs-along with a perceived hostility toward
buprenorphine and other opiate-replacement therapies .... 17 Treatment experts
observed that DEA's actions could have a chilling effect on family practitioners
and internal medicine specialists who have been encouraged to embrace the
treatment, but may grow tired of "all of the challenges one needs to surmount to
prescribe buprenorphine.,
128
Although the buprenorphine experience is promising, it may be too early to
tell whether the "use of buprenorphine in office based settings will ... lead the
United States to a more pragmatic attitude towards dealing with the consequences
of heroin addiction-and [whether] that . . . pragmatism will be long lasting
The "Bape" Fix, BALT. SUN, Dec. 16, 2007, at IA, available at http://articles.baltimoresun.com/2007-
12-16/news/0712160063_l.heroin-abuse-addicts, by requiring local jurisdictions to implement
diversion control plans. STATE OF MD. DEP'T OF HEALTH & MENTAL HYGIENE, STATEWIDE
BUPRENORPHINE INITIATIVE: DIVERSION CONTROL PLAN (Jan. 2, 2008), available at
http://www.maryland-adaa.org/content-documents/BuplnitiativeWeb/BupGuidelines.pdf
124. See Jaffe & O'Keeffe, supra note 8, at S10-11. If rescheduled as a Schedule II controlled
substance, buprenorphine would be subject to the same restrictions as methadone, limiting its
availability to OTPs. Id. One field director for Reckitt Benckiser regularly warns that "[tihe future of
buprenorphine for the treatment of opioid addiction rests in the hands of current prescribers." E-mail
from Anthony Tommasello, Field Med. Advisor, Reckitt Benckiser Pharm., Inc., to Ellen Weber,
Professor of Law, Univ. of Md. Sch. of Law (Dec, 21, 2009) (on file with author).
125. For example, under DATA 2000, physicians are the only "practitioners" authorized to prescribe
buprenorphine. 21 U.S.C. § 823(g)(2)(A), (B)(i) (2006 & West Supp. 2009). Permitting mid-level
practitioners who are otherwise authorized to prescribe medications, such as physician assistants and
nurse practitioners, to prescribe buprenorphine under supervision could expand care generally and
facilitate integrated treatment for HIV and opioid dependence. See Kresina et al., supra note 22, at 16
(noting the potential benefit of expanded prescribing capabilities); Bruce R. Schackman et al.,
Overcoming Policy and Financing Barriers to Integrated Buprenorphine and HIV Primary Care, 43
CLINICAL INFECTIOUS DISEASES (SuPP. 4) S247, S252 (2006) (calling for the creation of demonstration
projects to evaluate supervised distribution by mid-level practitioners).
126. Bob Curley, DEA Letter Sparks Fears About Intimidation of Buprenorphine Docs, JOIN
TOGETHER, Oct. 1, 2009, http://www.jointogether.org/news/features/2009/dea-letter-sparks-fears-
about.html.
127. Id. (reporting that DEA officials have denied that they are discouraging the use of
buprenorphine and claim the inspections are merely intended to carry out their regulatory
responsibilities).
128. Id. (reporting that the July 24, 2009 letter informed practitioners that they could exit the DATA
2000 program by filling out a form and, thereby, avoid inspection).
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.... ,129 An examination of the three other obstacles to physician prescribing
practices may shed more light on those prospects and the work that remains to be
done to reap the full benefits of pharmacotherapies for addiction treatment.
II. COMPETENCE AND COMFORT: THE EFFECT OF LIMITED MEDICAL SCHOOL
EDUCATION AND CLINICAL TRAINING IN ADDICTION MEDICINE
The historical failure of medical schools and residency programs to provide
adequate instruction in addiction and training in addiction medicine°130  a direct
consequence of the Harrison Act-undermines the capacity and willingness of
physicians to prescribe pharmacotherapies. 131 The exposure many medical students
and residents get to individuals with drug dependence, particularly in urban
teaching hospitals, is to those with active addiction rather than persons successfully
participating in treatment. 132 Seeing these individuals at their worst reinforces
perceptions that these patients do not do well and are unmotivated to recover,
133
and does little to promote positive attitudes about caring for this population.
134
Medical education in addiction is further handicapped by the limited number of
physician role models across clinical disciplines with expertise in addiction who
129. Jaffe & O'Keeffe, supra note 8, at S11.
130. Norman S. Miller et al., Why Physicians Are Unprepared to Treat Patients Who Have Alcohol-
and Drug-Related Disorders, 76 AcAD. MED. 410, 410, 413 (2001) (reporting that the average four-year
medical school devoted a total of twelve hours of curricular time to alcohol and drug use disorders);
Saxon & McCarty, supra note 5, at 122 (noting that, after the 1920s, physicians were discouraged from
treating heroin-dependent persons and medical school curricula provided no training in this area);
Schackman et al., supra note 125, at S248 (attributing the limited education and clinical experience in
addiction medicine to the separation of medical and substance abuse treatment); Joyce C. West et al.,
Challenges in Increasing Access to Buprenorphine Treatment for Opiate Addiction, 13 AM. J. ON
ADDICTIONS S8, S13 (2004) ("[M]ost medical residency training programs have historically not
included training related to the treatment of opiate addiction .... ).
131. See supra discussion accompanying notes 103 (lack of trained physicians cited by HHS as
rationale for rejecting office-based prescribing of methadone), 110 (failure of practitioners to understand
pharmacotherapy of methadone has contributed to overdose deaths among patients prescribed the drug
for pain management), and 114 (advising physicians prescribing pain medications to identify patients
with histories of alcohol and drug problems).
132. Interview with Dr. Christopher Welsh, Assoc. Prof. of Psychiatry, Univ. of Md. Sch. of Med.,
in Baltimore, Md. (Oct. 27, 2008) [hereinafter Welsh Interview].
133. John N. Chappel, Medical Education in Substance Abuse: The Acquisition of Knowledge,
Attitudes, and Skills, in SUBSTANCE ABUSE: A COMPREHENSIVE TEXTBOOK, 1269, 1276 (Joyce H.
Lowinson et al. eds., 4th ed. 2005).
134. Id. at 1276-78 (discussing the complex basis of negative attitudes about patients with alcohol
and drug use disorders, and concluding that "the best results, in terms of positive attitudes and skills,
occur when residents rotate through addiction treatment units and are supervised by experts in addiction
medicine . . ."); see also Schackman et al., supra note 125, at S248 (describing Seattle's methadone
medical maintenance treatment program in which generalist physicians were trained to provide
methadone treatment to stable patients and given expert clinical support as questions arose, and noting
that training resulted in physician satisfaction and more positive attitudes toward methadone treatment).
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can ensure that future generations of physicians develop the requisite attitudes,
skill, and knowledge needed to treat patients with addictive diseases.' 35
As a result, many physicians do not understand the biological underpinning of
addiction, which would promote the prescribing of effective medications, 136 or
consider addiction a treatable medical condition' 37 or, at least, one that they should
address. 138 Others view addiction pharmacotherapies as more difficult to prescribe
than other medications they routinely prescribe and manage for patients. 139 The
stereotypical views of addicts that permeate society generally also affect physicians
who respond by not wanting patients with addictions in their offices.140
135. Miller et al., supra note 130, at 410; see also Chappel, supra note 133, at 1278, 1283-84
(indicating that role models from the student or physician's clinical discipline have the greatest impact
on attitudes); D. Dwayne Simpson, A Conceptual Framework for Transferring Research to Practice, 22
J. SUBSTANCE ABUSE TREATMENT 171, 173 (2002) (noting the importance of organizational leadership
in adopting new technologies); Weinrich & Stuart, supra note 10, at 1346-47 (concluding that the
physician leadership in Scotland has been critical to expanding office-based methadone treatment).
136. See, e.g., Mark et al., supra note 8, at 225 ("Physicians who had read more about naltrexone
and were more confident in their knowledge of [the medication] ... prescribed it more often.").
137. TIP 49, supra note 2, at 45; see also West et al., supra note 130, at S14 fig.l (identifying
physician values and beliefs that affect diffusion of buprenorphine treatment, including stigma and
negative attitudes towards opiate addiction and its treatability; negative attitudes towards
pharmacological treatment of addiction; lack of training in addiction; and perception of addiction as a
medical problem).
138. See Chinazo 0. Cunningham et al., Attending Physicians' and Residents' Attitudes and Beliefs
About Prescribing Buprenorphine at an Urban Teaching Hospital, 38 FAM. MED. 336, 337 (2006). A
study of primary care/social medicine residents and attending physicians at six ambulatory clinics
associated with an urban university teaching hospital revealed that 83% cared for patients who use
heroin or misuse opioid prescriptions, but only 74% were comfortable discussing illicit drug use and
only half were comfortable discussing drug treatment. Id. The majority reported caring for patients with
substance use disorders by referring them to social workers, counselors, or drug treatment programs. Id.
Only 38% believed primary care physicians should prescribe buprenorphine, and 36% reported interest
in prescribing. Id. A survey of New York City physicians immediately prior to FDA approval of
buprenorphine, found that 36% would consider prescribing methadone and 26% would consider
prescribing buprenorphine if the medications were picked up at a pharmacy. Coffin et al., supra note 88,
at 3-4. The survey also revealed that 45% of respondents would not prescribe methadone and 42%
would not prescribe buprenorphine. Id. In a post-DATA 2000 study of psychiatrists to assess comfort in
prescribing buprenorphine, over 80% reported they would not be comfortable participating in office-
based treatment, even though this specialty has a greater proportion of patients who suffer from opiate
addiction. West et al., supra note 130, at S9-10.
139. Saxon & McCarty, supra note 5, at 126. Contra TIP 49, supra note 2, at 45-46 (discussing
treatment experts view that initiating pharmacotherapy for alcoholism is no more difficult than
beginning to prescribe an anti-depressant or anti-hypertensive medication, and that monitoring these
medications is less difficult than medication regimens for diabetes and coronary disease).
140. YNGVILD OLSEN ET AL., TREATING OPIOID ADDICTION 1N OFFICE BASED SErTNGS: FINDINGS
FROM A PHYSICIAN SURVEY 10-11 (2004), available at
http://www.healthymaryland.org/pdf/2004/2OPhysician/2OSurvey.pdf (reporting in a survey of
Maryland physicians that half of the physicians who were unwilling to prescribe buprenorphine
"believed that opioid addiction treatment is beyond the scope of practice for an office-based physician,"
that patients with addiction do not want to change their habit, and that having opiate addicted patients in
their offices is undesirable); Saxon & McCarty, supra note 5, at 123 (citing physician perceptions of
addiction patients as "drug seeking, demanding, manipulative, irresponsible, and respond[ing] poorly to
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A second "comfort" factor related to patient medical characteristics emerges
among physicians who are willing to prescribe pharmacotherapies for persons with
opiate addictions. This patient population often presents multiple medical and
psychosocial needs that make their care more difficult than that of the average
patient. 14 1 Maryland physicians engaged in office-based buprenorphine treatment
report that patient care requires increased time and attention to address the patient's
psychosocial and behavioral issues as well as third-party payer reimbursement
obstacles. 142 Patients often present with a need for immediate treatment because
they are in withdrawal and the detoxification process affects office staff and other
patients. 143 Patients with co-occurring, psychiatric disorders may not be appropriate
for primary care practices and may require care from a psychiatrist.'
44
Physician resistance and negative attitudes are not intractable, however.
Physicians in the United States have shown that they can treat other complex and
stigmatized disorders, such as depression and HIV, with appropriate training,
clinical experience, guidance, and effective pharmacotherapies. 145 The same is true
in the addiction context. Research has shown that physicians who have experience
providing primary care to patients who were known to participate in methadone
treatment express a far greater willingness to prescribe medication in an office-
based setting.146 Other studies have concluded that substantial majorities of primary
care physicians are willing to prescribe buprenorphine if provided appropriate
training and support.1
47
treatment"); West et al., supra note 130, at S14 fig. 1 (identifying perceived risks that affect physician
adoption of buprenorphine, including desirability and complexity of population and concerns about
patients in office not responding to the medication).
141. McNeely et al., supra note 88, at 100-01; see also CTR. FOR A HEALTHY MD., INC. & MEDCHI,
MD. STATE MED. SOC'Y, IMPROVING PATIENT ACCESS TO BUPRENORPHINE TREATMENT THROUGH
PHYSICIANS OFFICES IN MARYLAND: SUMMARY OF FINDINGS, RECOMMENDATIONS, AND ACTION STEPS
4 (2007), available at http://www.healthymaryland.org/pdf/Improving%20Patient%20Access%20for
%20Bup%2OTreatment.pdf (summarizing that physicians certified to prescribe buprenorphine reported
that the behavioral and psychosocial factors associated with addiction make addiction treatment different
from other diseases) [hereinafter CTR. FOR A HEALTHY MD.].
142. Id. at 4-5; see also infra Part III (discussing the cost of care in office-based practice).
143. CTR. FORA HEALTHY MD., supra note 141, at 4, 6.
144. See, e.g., Nat'l Guideline Clearinghouse, Mental Health Disorders Among Substance-Using
HIV-Infected Patients 6, 8 (2008), http://www.guideline.gov/summary/pdf.aspxdocid=12276.
145. Fiellin & O'Connor, supra note 2, at 691.
146. See OLSEN ET AL., supra note 140, at 8 (indicating that 36% of physicians were willing to
prescribe buprenorphine to an established patient with opioid dependence compared to 28% of
physicians willing to prescribe to a new patient); McNeely et al., supra note 88, at 99 Ibis. II, Ill
(reporting that among a sample of physicians, 99% of whom had provided care to a patient who
participated in a methadone treatment program, 70% were comfortable managing the care of a drug user
and 66% would prescribe medication if given proper training and support).
147. Cunningham et al., supra note 138, at 337-38 (finding that 72% of resident and attending
physicians ambulatory clinics in New York would be willing to prescribe buprenorphine if given
appropriate training and support, and citing similar results in studies of directors of primary care and
HIV clinics and pharmacists).
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The federal government has stepped in to provide a short-term antidote to
inadequate medical school training and physician role models. The Substance
Abuse and Mental Health Services Administration has published detailed treatment
guidelines on the diagnosis of alcoholism and drug dependence and use of
pharmacotherapies, 14 8 and Congress has mandated education in the case of
buprenorphine.149 As part of a pre-DATA 2000 study, the National Institute on
Drug Abuse funded a team of expert physicians to recruit and train physicians in
several states to prescribe buprenorphine in an office-based practice and
demonstrated feasibility and physician satisfaction.1 50 A federally-funded Physician
Clinical Support System now exists to provide mentoring in the use of
pharmacotherapies 5 1 Nonetheless, the long-term solution for adequate training is
for "the medical education system ... to support mechanisms that develop
appropriate practice patterns by physicians and allow for increased training and
experience in caring for... [alcohol and drug dependent] patients.' ' 52
International models offer possible strategies that would assist physicians in
treating patients who present greater psychosocial and behavioral needs. The
United Kingdom has implemented a "shared care" model that links general
practitioners with drug counselors and public health workers who consult on
difficult patients, review practices, and help resolve problems.153 Physicians are
already required, under DATA 2000, to have the capacity to refer patients for
appropriate counseling and other ancillary services,' 5 4 but office-based physicians
may also require assistance internally.155 Overcoming the historical separation
between the primary care and specialty treatment systems and creating functional
relationships between the two (as opposed to a one-way referral system) will be
essential under a shared care model.
148. See, e.g., TIP 49, supra note 2, at xii (stating that the goal of TIP 49 is to "provide[] the basic
information, evidence- and consensus-based guidelines ... necessary to help health-care practitioners
treat patients with [alcohol use disorders]"); TIP 40, supra note 116, at viii ("The goal of this TIP [40] is
to provide information that physicians can use to make practical and informed decisions about the use of
buprenorphine to treat opioid addiction.").
149. See supra note 21. Physicians must first have the motivation to obtain the training and apply for
certification to prescribe buprenorphine.
150. Saxon & McCarty, supra note 5, at 124-25.
151. See supra note 118.
152. Fiellin & O'Connor, supra note 2, at 691; see also Welsh Interview, supra note 132 (noting that
residents will gain exposure to office-based buprenorphine only through physicians who are certified to
prescribe).
153. McNeely et al., supra note 88, at 101 (describing the United Kingdom's experience); Weinrich
& Stuart, supra note 10, at 1346 (describing Scotland's experience).
154. 21 U.S.C. § 823(g)(2)(B)(ii) (2006 & West Supp. 2009).
155. See Alexander Y. Walley et al., Office-Based Management of Opioid Dependence with
Buprenorphine: Clinical Practices and Barriers, 23 J. GENERAL INTERNAL MED. 1393, 1396 (2008)
("[P]roviders adding [office-based opioid treatment] with buprenorphine to one's practice require[]
increased administrative and clinical resources.").
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III. COMPENSATION: BARRIERS TO COVERING THE COST OF CARE IN AN OFFICE-
BASED PRACTICE
Physicians must be assured of adequate compensation if they are to offer
medication-assisted treatment in their office-based practice. 156 Unlike the French
health insurance program, which completely subsidizes office-based buprenorphine
treatment, 157 physicians in the United States must contend with a wide range of
commercial and public (i.e., Medicaid and Medicare) insurance plans that restrict
patient access to care and physician reimbursement.' 58 Compensation issues affect
the willingness to offer this service even among those physicians who are inclined
to prescribe pharmacotherapy for persons with addictions.' 59
Addiction treatment in the United States has suffered historically from a lack
of parity in insurance coverage. 16 Insurance plans routinely impose treatment
limitations and financial requirements on addiction benefits that are not only
different from the coverage for other medical conditions but also fail to recognize
that addiction is a chronic medical condition.16 ' Thus, plans restrict the number and
frequency of office visits and increase the amount of patient co-payments as
treatment is extended. 62 These underwriting practices impede the delivery of
office-based care that requires a longer (and perhaps indefinite) duration of
treatment for optimal outcomes and more intensive services at various times to
156. Saxon & McCarty, supra note 5, at 126 (observing that physicians are unlikely to actively seek
addiction patients unless they receive financial incentives equal to those for other patients); Interview of
Dr. Jerome Jaffe, Clinical Professor, Univ. of Md. Sch. of Med., in Baltimore, Md. (Oct. 27, 2008)
(explaining that the treatment of patients with addictions must add value to a physician's practice and
that reimbursement is not adequate for care of patients with buprenorphine).
157. Carrieri, supra note 10, at S 199.
158. See Saxon & McCarty, supra note 5, at 123 (discussing the "[s]ocial, economic, and political
forces . . . [that] work against more widespread use and delivery of addiction treatments," including
limited government and private funding sources).
159. OLSEN ET AL., supra note 140, at 9, 17 tbl.3 (reporting that among physicians willing to
prescribe buprenorphine, adequate reimbursement ranked as item of greatest need).
160. Saxon & McCarty, supra note 5, at 123. The Paul Wellstone and Pete Domenici Mental Health
Parity and Addiction Equity Act of 2008 (MHPAEA), effective October 2009, may begin to address
some insurance barriers. Pub. L. No. 110-343, § 512, 122 Star. 3881 (codified as amended in scattered
sections of 26, 29, 42 U.S.C.). The MHPAEA prohibits different or separate treatment limitations and
financial requirements for substance use and medical/surgical benefits in most commercial and Medicaid
managed care policies. 26 U.S.C.A. § 9812(a)(3)(A) (West Supp. 2009); 29 U.S.C.A. § 1185a(a)(3)(A)
(West Supp. 2009); 42 U.S.C.A. § 300gg-5(a)(3)(A) (West Supp. 2009). The MPHAEA does not require
health insurance plans to provide coverage for addiction treatment or medications, and parity
requirements only apply to the extent the policy offers coverage for substance use disorders. E.g., 26
U.S.C.A. § 9812(a)(I)(A), (2)(A).
161. A. Thomas McLellan et al., Drug Dependence, A Chronic Medical Illness: Implications for
Treatment, Insurance, and Outcomes Evaluation, 284 JAMA 1689, 1694 (2000); see also Heilig & Egli,
supra note 2, at 856 (discussing alcohol dependence as a chronic relapsing disease); Saitz et al., supra
note 1, at 55 (discussing drug and alcohol dependence from a chronic disease management perspective).
162. Cf A. Thomas McLellan et al., supra note 161, at 1693-94 (supporting insurance parity
initiatives that do not limit the number and frequency of office visits covered).
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address relapse. In addition, reimbursement rates often do not compensate
adequately for the intensity of the service that must be provided to patients who
require counseling for their psychosocial needs.
16 3
Insurance coverage for medication is a separate and often complicated issue.
Insurance plans may or may not include medications for alcoholism and opioid
dependence in their formularies, 164 and those that do may impose restrictions on the
long-term use of costly medications like buprenorphine and naltrexone.' 65 A
patient's ability to cover the cost of these medications out-of-pocket over the long
term can be cost-prohibitive, can lead to patient compliance problems, 66 and has
been identified as a factor that affects physician prescribing decisions.167
Some insurance plans also impose prior authorization requirements for
medication reimbursement-a common insurance practice, but one that is uniquely
incompatible with the need to deliver immediate care to a patient in the throes of
opioid withdrawal in the doctor's office. 68 Any delay in the delivery of
medications can result in patient distress and the risk of adverse medical outcomes,
or the patient being lost to treatment.' 69 Satisfying preauthorization requirements
for current patients who need to refill prescriptions can also consume substantial
time. 170 Private physicians, who already contend with reimbursement restrictions
and high patient volume under managed care contracts, must have adequate
administrative staff to address these insurance issues alone.171
A physician's reluctance to provide medication-assisted treatment in the
highly variable insurance context is understandable, particularly when balancing
the needs of this patient population against the physician's existing patients.
172
Some physicians attempt to work around low reimbursement rates and other
insurance barriers by requiring patients to pay directly for physician services
instead of billing the patient's insurance plan. 173 This administrative solution
clearly excludes or inappropriately shortens the length of care for those without
163. CTR. FORA HEALTHY MD., supra note 141, at 9.
164. Schackman et al., supra note 125, at S249 (reporting that every state Medicaid program but two
include buprenorphine in their formularies, although state Medicaid programs may impose separate
restrictions, and that, as of 2006, buprenorphine was not listed on model guidelines for Medicare
prescription drug benefits).
165. CTR. FOR A HEALTHY MD., supra note 141, at 5.
166. Id.
167. Mark et al., supra note 8, at 226 ("Physicians ranked cost [of naltrexone] as the second most
common reason ... [for] not prescrib[ing] ... to more patients.").
168. CTR. FORA HEALTHY MD., supra note 141, at 5.
169. Id.
170. Id.
171. Welsh Interview, supra note 132.
172. See CTR. FOR A HEALTHY MD., supra note 141, at 5-6 (noting that physicians are required to
make practice management decisions regarding buprenorphine because of the substantial burden
imposed on the health care provider by patients and insurers).
173. Id. at 5.
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adequate resources. 74 These administrative burdens and reimbursement barriers
may also result in physicians limiting the number of patients with opioid
dependence who they are willing to treat.
75
National health care reform, if enacted, may begin to address some of the
systemic compensation barriers. Both the Senate- and House-passed bills would
require the coverage of substance use disorders in the essential benefit package and
require enforcement of the current Mental Health Parity and Addiction Equity Act
standards in individual, small group, and large group plans. 76 Equitable health care
coverage is necessary to address an obstacle that will restrict office-based practice
even if physician training improves.
CONCLUSION
The continuing role of law enforcement in shaping the public's perception of
persons with alcohol and drug addiction, and the addiction treatment system itself,
will undoubtedly result in slow and cautious advances in the use of
pharmacotherapies for addiction. 177 The diffusion of addiction medications in
physician office-based practices will depend upon ongoing research that documents
the safe and effective use of medications outside of heavily regulated or specialty
care settings and satisfaction by both physicians and patients. 78 Evidence-based
research may be the most effective response to overly aggressive enforcement
efforts that deem diversion the primary harm to be addressed.
Progress must also occur simultaneously on several different health care
fronts. Medical schools and residency programs must do more to educate all
physicians about addiction, the need for universal screening of alcohol and drug use
disorders, and the evidence-based options for managing this chronic disease. 179 The
medical profession and specialty addiction treatment system must develop more
seamless relationships so that physicians can obtain timely and effective support
when caring for patients with addiction. 80 Health insurance plans must structure
benefit coverage for substance use disorders in a way that will facilitate treatment
under a chronic disease model and reimburse physicians adequately for labor-
174. See id. (noting the concern of physicians that patients' inability to pay will cause them to
decrease dosages before they are ready).
175. See id. at 6 (indicating that a number of physicians "were unsure if they would increase the
number of patients [that] they treat" due to "[tlhe intensity of demand on physicians from both patients
and payers...").
176. Affordable Health Care for America Act, HR. 3962, 111 th Cong. § 222 (2009) (benefit);
§ 214(b) (parity); Patient Protection and Affordable Care Act, H.R. 3590, 111 th Cong. § 1302 (2009)
(benefit); § 1311 (j) (parity).
177. See supra Part I.
178. See supra notes 18-28 and accompanying text.
179. See supra Part II.
180. See supra notes 151-55 and accompanying text.
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intensive, office-based services.' 81 Persons with substance use disorders and their
families must advocate for more accessible, readily available, and less stigmatizing
treatment options. 182 Finally, policymakers must begin to incorporate harm
reduction strategies in our drug policies, just as we use various tools to reduce the
harmful consequences of smoking, alcohol use, and other public health
problems. 83 Medication use in office-based practices is an important harm
reduction strategy that will likely increase access to treatment in the United States
and "demonstrate what can be achieved by easier and less stigmatizing access" to
care. 184 Although these efforts all involve paradigm shifts, they are long over-due
and are necessary to reduce the toll of addiction in the United States.
185
181. See supra Part III.
182. See supra notes 25-26 and accompanying text.
183. See supra notes 10-17 and accompanying text.
184. Jaffe & O'Keeffe, supra note 8, at SI 1.
185. See supra note 28 and accompanying text.
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